Price
No data yet.
Social Signal Score
Analyst Ratings
18 analystsRevenue
$1.02B+89.12%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gael Touya
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 14,000
- Beta
- 0.32
- Country
- US
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.12
Financials
Revenue
$1.02B+89.1%Net Income
$32.60M-34.2%EBITDA
$151.67M+39.3%Free Cash Flow
$98.59M+14.3%EPS (diluted)
$0.51-33.8%Shares Outstanding (diluted)
64.15M-0.1%Operating Expenses
$160.16MCash & Debt
$212.30MReturn of Capital
$60.52MRevenue by Segment (annual)
$3.05BDividend per Share
$0.50Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $3.78B | $392.79M | $5.97 |
| 2024 | $3.58B | $374.54M | $5.65 |
| 2023 | $3.49B | $284.49M | $4.34 |
| 2022 | $3.32B | $239.29M | $3.66 |
| 2021 | $3.23B | $244.10M | $3.72 |
| 2020 | $2.93B | $214.04M | $3.32 |
| 2019 | $2.86B | $242.20M | $3.81 |
| 2018 | $2.76B | $194.75M | $3.12 |
| 2017 | $2.47B | $220.03M | $3.52 |
| 2016 | $2.33B | $205.59M | $3.27 |
| 2015 | $2.32B | $199.35M | $3.19 |
| 2014 | $2.60B | $191.66M | $2.95 |
| 2013 | $2.52B | $171.99M | $2.60 |
| 2012 | $2.33B | $162.61M | $2.45 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ATR's reported EPS growth of 7.1% a year over 13 years.
- EPS in 5 years
- $8.42
- Implied price
- $168.39
- Return from $140.08
- 3.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $83.72 — -40.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -2.9% | -12.4% | -8.9% | -5.9% | -3.3% | -0.9% |
| 2.1% | -7.9% | -4.3% | -1.1% | 1.7% | 4.2% |
| 7.1% | -3.4% | 0.4% | 3.7% | 6.7% | 9.3% |
| 12.1% | 1.1% | 5.1% | 8.6% | 11.7% | 14.4% |
| 17.1% | 5.6% | 9.8% | 13.4% | 16.7% | 19.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
10-80.00%Social Signal Score
Mentions (22)
- News (RSS)seekingalpha·9d ago·Negative
Cytosorbents outlines early 2027 DrugSorb-ATR De Novo plan with $300M initial U.S./Canada market
View source ↗ - 4chan /biz/biz·17d ago·Neutral
>>62858300 I think TA and price levels are meaningless on leveraged etfs. No this isnt about chop or rebalancing I think 1x sector etfs more accurately measure the price. You cant think in terms of $ amounts, it has to be percentages and moves that expand the ATR
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Rakovina Therapeutics to Present Brain-Penetrant ATR Inhibitor Data at the 31st Society for Neuro-Oncology Annual Meeting Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours Poster to highlight AI-designed kt-5000AI compounds developed for PTEN-deficient brain tumours
View source ↗ - Newszacks.com·20d ago·Positive
Investing in AptarGroup (ATR)? Don't Miss Assessing Its International Revenue Trends Examine AptarGroup's (ATR) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
View source ↗ - Newsprnewswire.com·20d ago·Positive
Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Reversed and Improved Features of PRKAG2 Syndrome During HCMS at AHA Scientific Sessions 2026 -- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation ofcardiac glycogen and cardiac hypertrophy -- -- Data further reinforce scientific rationale for ATR 1072 targeting the root cause ofPRKAG2 syndrome -- -- Poster presentation November 6 at 5:30 p.m. CT -- SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Atrium Thera…
View source ↗ - News (RSS)fool·22d ago·Positive
Aptar (ATR) Q3 2026 Earnings Call Transcript Russian deconsolidation and margin pressures offset strong sales growth across segments.
View source ↗ - News (RSS)seekingalpha·23d ago·Positive
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript
View source ↗ - Newsseekingalpha.com·23d ago·Positive
AptarGroup, Inc. (ATR) Q3 2026 Earnings Call Transcript AptarGroup, Inc. ( ATR ) Q3 2026 Earnings Call October 30, 2026 9:00 AM EDT Company Participants Marry Skafidas - Senior Vice President of Investor Relations & Communications Gael Touya - CEO, President & Director Vanessa Kanu - Executive VP & CFO Conference Call Participants Ghansham Panjabi - Robert W. Baird & Co. Incorporated, Research Division Paul Knight - KeyBanc Capital Markets Inc., Research Division Matthew Roberts - Raymond James …
View source ↗ - News (RSS)seekingalpha·23d ago·Neutral
AptarGroup, Inc. 2026 Q3 - Results - Earnings Call Presentation
View source ↗ - News (Marketaux)seekingalpha.com·23d ago·Neutral
AptarGroup, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:ATR) 2026-10-30 AptarGroup, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:ATR) 2026-10-30
View source ↗ - Newsmarketbeat.com·23d ago·Neutral
What AptarGroup (ATR) Said on Its Q3 Earnings Call AptarGroup NYSE: ATR reported third-quarter 2026 sales growth across its three business segments, while adjusted profitability declined from the prior year as emergency medicine destocking and lower margins in Beauty and Closures weighed on results.
View source ↗ - Newszacks.com·24d ago·Positive
AptarGroup (ATR) Q3 Earnings and Revenues Beat Estimates AptarGroup (ATR) came out with quarterly earnings of $1.52 per share, beating the Zacks Consensus Estimate of $1.46 per share. This compares to earnings of $1.62 per share a year ago.
View source ↗ - Newsglobenewswire.com·25d ago·Negative
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research EMphora™ platform integrates clinical evidence and predictive modelling to help identify promising cancer patient populations and guide the next phase of research
View source ↗ - Newszacks.com·48d ago·Neutral
AptarGroup (ATR) Loses 5.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner AptarGroup (ATR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newszacks.com·58d ago·Negative
3 Packaging Stocks Worth Watching Despite Industry Pressure Although weak demand and tariffs cloud the Zacks Containers - Paper and Packaging industry's near-term outlook, AVY, ATR and KRT are navigating the challenges well.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript AptarGroup, Inc. (ATR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - News (Marketaux)gurufocus.com·69d ago·Positive
ATR Looks 22.3% Undervalued on GF Value™ Amid Strong Dividend Profile On September 14, 2026, AptarGroup</e[+191 characters]
View source ↗ - News (RSS)seekingalpha·74d ago·Positive
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·74d ago·Positive
AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript AptarGroup, Inc. (ATR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·81d ago·Negative
…rbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings Patient-level matched analysis of real-world data demonstrated a significant 37% relative reduction in severe bleeding Significant reductions in 24-hour chest tube drainage and red blood cell transfusions were also seen, with no serious device-related adverse events reported Findings reinforce results…
View source ↗ - News (RSS)economictimes·83d ago·Neutral
'Fly91 close to ordering at least 20 ATR turboprops'
View source ↗ - Newsprnewswire.com·101d ago·Negative
Atrium Therapeutics Reports Second Quarter 2026 Financial Results -- IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome -- -- Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb -- SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) ("Atrium," "Atrium Therapeutics," or the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted t…
View source ↗
Earnings
Thu, Feb 4(in 2 months)
Consensus estimate $1.42 per share
Typical surprise +3.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Oct 29$1.52 vs $1.47beat
- Thu, Jul 30$1.42 vs $1.35beat
- Thu, Apr 30$1.19 vs $1.15beat
- Thu, Feb 5$1.25 vs $1.24beat
- Thu, Oct 30$1.62 vs $1.57beat
- Thu, Jul 31$1.66 vs $1.58beat
Estimates and results for ATR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATR officers and directors.
- Bought
- —
- Sold
- $5.5m
0 trades
16 trades
- Prieur Marcsold
- Vinczeller Shielasold
- Touya Gaelsold
- Touya Gaelsold
- Prieur Marcsold
- Prieur Marcsold
- Tanda Stephan B.sold
- Tlili Hedisold
84 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (31d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Jul 13, 2026 (25d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 10, 2025 (21d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (21d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Oct 13, 2025 (32d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 18, 2024 (23d later)Sell$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (43d later)Buy$15,001 - $50,000
- Michael T. McCaulhouse · TX10 · disclosed Dec 14, 2023 (43d later)Buy$1,001 - $15,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (42d later)Buy$50,001 - $100,000
- Michael T. McCaulhouse · TX10 · disclosed Sep 19, 2022 (42d later)Buy$50,001 - $100,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2022 (22d later)Buy$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Oct 21, 2019 (38d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Oct 21, 2019 (40d later)Sell$1,001 - $15,000
- Susie Leehouse · NV03 · disclosed Aug 29, 2019 (48d later)Sell$1,001 - $15,000
- Elizabeth Pannill Fletcherhouse · TX07 · disclosed Apr 23, 2019 (56d later)Sell$1,001 - $15,000
- Brad Schneiderhouse · IL10 · disclosed Apr 6, 2019 (32d later)Sell$250,001 - $500,000
- Brad Schneiderhouse · IL10 · disclosed Feb 17, 2019 (12d later)Buy$250,001 - $500,000
- David McKinleyhouse · WV01 · disclosed Jan 9, 2019 (23d later)Sell$15,001 - $50,000
- David McKinleyhouse · WV01 · disclosed Jan 9, 2019 (20d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
